Adolescent
13 - 17 years of age
Vaccinations
-
-
- Prevention of COVID-19 disease
- Reduction in severity of COVID-19 disease if contracted
- Reduction in hospitalization and death due to COVID-19 disease
-
-
-
- The Pfizer-BioNTech COVID-19 vaccine is authorized for use in individuals aged 5 years and older.
- The Moderna COVID-19 vaccine is authorized for use in individuals aged 18 years and older.
- The Johnson & Johnson COVID-19 vaccine is authorized for use in individuals aged 18 years and older.
- The AstraZeneca COVID-19 vaccine is authorized for use in individuals aged 18 years and older.
- The Sinovac COVID-19 vaccine is authorized for use in individuals aged 18 years and older.
- The Sinopharm COVID-19 vaccine is authorized for use in individuals aged 18 years and older.
-
-
-
- Pregnancy or breastfeeding
- Individuals with compromised immune systems
- History of severe allergic reactions
- Acute illness or fever
- Receiving other vaccines
- History of Guillain-Barré syndrome (GBS)
-
-
-
- Development of mRNA vaccines, which use genetic material to induce an immune response
- Increased understanding of the immune response to COVID-19 and how to target it with vaccines
- Approval of additional vaccine formulations, such as the Johnson & Johnson vaccine, which requires only one dose
- Continued research into new vaccine technologies, such as viral vector and protein subunit vaccines
- Studies on the effectiveness of booster doses and the development of variant-specific vaccines
-
-
-
- Fatigue
- Headache
- Body aches
- Chills
- Fever
- Nausea
- Injection site pain or swelling
-
-
-
- People with a history of severe allergic reactions to any component of the COVID-19 vaccine should not receive the vaccine.
- People who have had a severe allergic reaction to the first dose of the COVID-19 vaccine should not receive the second dose.
- People who are currently experiencing COVID-19 symptoms or are in quarantine should not receive the vaccine until they have fully recovered and completed their quarantine period.
- People who have received another vaccine recently should talk to their healthcare provider before getting the COVID-19 vaccine.
- People who are immunocompromised or taking immunosuppressive medications should talk to their healthcare provider before getting the COVID-19 vaccine.
- Children under the age of 12 are not yet eligible to receive the COVID-19 vaccine.
- Women who are pregnant or breastfeeding should talk to their healthcare provider before getting the COVID-19 vaccine.
-
-
-
-
- What is vaccine efficacy?
- Vaccine efficacy refers to the ability of a vaccine to prevent the disease it targets under ideal and controlled conditions.
- It is calculated by comparing the incidence of the disease in vaccinated individuals versus unvaccinated individuals.
- What is vaccine efficacy?
-
-
-
-
-
- What is the efficacy of Covid-19 vaccines?
- The efficacy of Covid-19 vaccines varies depending on the type of vaccine and the population it is tested on.
- For example, the Pfizer-BioNTech vaccine has an efficacy of 95% in preventing symptomatic Covid-19 in adults aged 16 and older, while the Moderna vaccine has an efficacy of 94.1% in the same population.
- The Johnson & Johnson vaccine has an overall efficacy of 66.3% in preventing moderate to severe Covid-19 globally.
- What is the efficacy of Covid-19 vaccines?
-
-
-
-
- What do these efficacy rates mean?
- These efficacy rates mean that vaccinated individuals are significantly less likely to develop symptomatic Covid-19 compared to unvaccinated individuals.
- However, it is still possible for vaccinated individuals to contract and spread the virus, although the risk is significantly lower.
- It is important to note that these efficacy rates were obtained under ideal and controlled conditions, and the effectiveness of the vaccines in real-world settings may vary.
- What do these efficacy rates mean?
-
-
-
- Booster doses are additional doses of COVID-19 vaccine given after the initial series of doses to extend the duration of protection against the virus.
- Booster doses are recommended for certain individuals, including those who are immunocompromised and those who received the Johnson & Johnson vaccine.
- Booster doses for the general population may be recommended based on the ongoing assessment of vaccine effectiveness against emerging variants and the duration of vaccine protection.
- The timing and need for booster doses may vary depending on the type of vaccine received, individual characteristics such as age and underlying health conditions, and other factors.
- Individuals should consult with their healthcare provider or local health department to determine if they are eligible and recommended to receive a booster dose.
-
-
-
- The COVID-19 vaccines are safe and effective at preventing COVID-19 infection, hospitalization, and death.
- The vaccines have undergone rigorous testing and clinical trials, including large-scale studies involving tens of thousands of participants.
- The vaccines have been granted emergency use authorization (EUA) by regulatory agencies around the world, including the FDA in the United States.
- Reports of adverse events following vaccination are rare, and the benefits of vaccination outweigh the risks for most people.
- Common side effects of the COVID-19 vaccines include pain and swelling at the injection site, fever, fatigue, headache, and muscle aches. These side effects are usually mild to moderate in severity and go away on their own within a few days.
- Serious allergic reactions to the COVID-19 vaccines are very rare, occurring in less than 1 in a million doses administered. People who have a history of severe allergic reactions to any component of the COVID-19 vaccines should not receive the vaccine.
- The CDC and FDA are closely monitoring vaccine safety and investigating any reports of adverse events following vaccination.
-
-
-
- The COVID-19 vaccines have shown efficacy against multiple variants of the virus, including the Alpha, Beta, Gamma, and Delta variants.
- Studies have shown that the vaccines provide high levels of protection against severe illness, hospitalization, and death caused by these variants.
- However, some studies have shown that the vaccines may be less effective at preventing symptomatic infections or transmission of some variants, such as the Delta variant.
- Researchers are continuing to study the efficacy of the vaccines against new variants as they emerge.
- Public health officials and vaccine manufacturers are monitoring the situation closely and developing plans for potential booster shots or updated vaccine formulations if needed to address new variants.
-